BioVersys to Present Alpibectir Data at Global Lung Health Conference

BioVersys AG, a clinical-stage biopharmaceutical company, announced plans to present new data on alpibectir at The Union World Conference on Lung Health. The event will occur from November 17 to 20, 2026, in Rio de Janeiro, Brazil. Alpibectir, developed with GSK, is being tested in combination with ethionamide for treating drug-sensitive pulmonary tuberculosis.

The company will showcase findings from various studies, including the ENABLE trial. BioVersys' presentations will cover early bactericidal activity, safety, and pharmacokinetics of the alpibectir-ethionamide combination. Alpibectir has received orphan drug designations from both the U.S. FDA and the EMA, offering market exclusivity incentives.